Browsing by Author "Gainetdinov, Raul R"

Now showing 1 - 4 of 4
  • Thumbnail Image
    ItemOpen Access
    Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice.
    (J Neurosci, 2003-11-12) Bohn, Laura M; Gainetdinov, Raul R; Sotnikova, Tatyana D; Medvedev, Ivan O; Lefkowitz, Robert J; Dykstra, Linda A; Caron, Marc G
    The reinforcing and psychomotor effects of morphine involve opiate stimulation of the dopaminergic system via activation of mu-opioid receptors (muOR). Both mu-opioid and dopamine receptors are members of the G-protein-coupled receptor (GPCR) family of proteins. GPCRs are known to undergo desensitization involving phosphorylation of the receptor and the subsequent binding of beta(arrestins), which prevents further receptor-G-protein coupling. Mice lacking beta(arrestin)-2 (beta(arr2)) display enhanced sensitivity to morphine in tests of pain perception attributable to impaired desensitization of muOR. However, whether abrogating muOR desensitization affects the reinforcing and psychomotor properties of morphine has remained unexplored. In the present study, we examined this question by assessing the effects of morphine and cocaine on locomotor activity, behavioral sensitization, conditioned place preference, and striatal dopamine release in beta(arr2) knock-out (beta(arr2)-KO) mice and their wild-type (WT) controls. Cocaine treatment resulted in very similar neurochemical and behavioral responses between the genotypes. However, in the beta(arr2)-KO mice, morphine induced more pronounced increases in striatal extracellular dopamine than in WT mice. Moreover, the rewarding properties of morphine in the conditioned place preference test were greater in the beta(arr2)-KO mice when compared with the WT mice. Thus, beta(arr2) appears to play a more important role in the dopaminergic effects mediated by morphine than those induced by cocaine.
  • Thumbnail Image
    ItemOpen Access
    Social context-dependent singing-regulated dopamine.
    (J Neurosci, 2006-08-30) Sasaki, Aya; Sotnikova, Tatyana D; Gainetdinov, Raul R; Jarvis, Erich D
    Like the mammalian striatum, the songbird striatum receives dense dopaminergic input from the midbrain ventral tegmental area-substantia nigra pars compacta complex. The songbird striatum also contains a unique vocal nucleus, Area X, which has been implicated in song learning and social context-dependent song production. Area X shows increased neural firing and activity-dependent gene expression when birds sing, and the level of activation is higher and more variable during undirected singing relative to directed singing to other birds. Here we show in the first report of in vivo microdialysis in awake, behaving songbirds that singing is associated with increased dopamine levels in Area X. Dopamine levels are significantly higher with directed relative to undirected singing. This social context-dependent difference in dopamine levels requires the dopamine transporter, because local in vivo blockade of the transporter caused dopamine levels for undirected singing to increase to levels similar to that for directed singing, eliminating the social context-dependent difference. The increase in dopamine is presumably depolarization and vesicular release dependent, because adding of high K+ increased and removal of Ca2+ increased and decreased extracellular DA levels. Our findings implicate DA and molecules that control DA kinetics in singing behavior and social context-dependent brain function.
  • Thumbnail Image
    ItemOpen Access
    The dopamine metabolite 3-methoxytyramine is a neuromodulator.
    (PLoS One, 2010-10-18) Sotnikova, Tatyana D; Beaulieu, Jean-Martin; Espinoza, Stefano; Masri, Bernard; Zhang, Xiaodong; Salahpour, Ali; Barak, Larry S; Caron, Marc G; Gainetdinov, Raul R
    Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia.
  • Thumbnail Image
    ItemOpen Access
    The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment.
    (Sci Rep, 2012) Managò, Francesca; Espinoza, Stefano; Salahpour, Ali; Sotnikova, Tatyana D; Caron, Marc G; Premont, Richard T; Gainetdinov, Raul R
    G protein-coupled Receptor Kinase 6 (GRK6) belongs to a family of kinases that phosphorylate GPCRs. GRK6 levels were found to be altered in Parkinson's Disease (PD) and D(2) dopamine receptors are supersensitive in mice lacking GRK6 (GRK6-KO mice). To understand how GRK6 modulates the behavioral manifestations of dopamine deficiency and responses to L-DOPA, we used three approaches to model PD in GRK6-KO mice: 1) the cataleptic response to haloperidol; 2) introducing GRK6 mutation to an acute model of absolute dopamine deficiency, DDD mice; 3) hemiparkinsonian 6-OHDA model. Furthermore, dopamine-related striatal signaling was analyzed by assessing the phosphorylation of AKT/GSK3β and ERK1/2. GRK6 deficiency reduced cataleptic behavior, potentiated the acute effect of L-DOPA in DDD mice, reduced rotational behavior in hemi-parkinsonian mice, and reduced abnormal involuntary movements induced by chronic L-DOPA. These data indicate that approaches to regulate GRK6 activity could be useful in modulating both therapeutic and side-effects of L-DOPA.